JP5980775B2 - 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤 - Google Patents

疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤 Download PDF

Info

Publication number
JP5980775B2
JP5980775B2 JP2013510313A JP2013510313A JP5980775B2 JP 5980775 B2 JP5980775 B2 JP 5980775B2 JP 2013510313 A JP2013510313 A JP 2013510313A JP 2013510313 A JP2013510313 A JP 2013510313A JP 5980775 B2 JP5980775 B2 JP 5980775B2
Authority
JP
Japan
Prior art keywords
formulation
use according
methotrexate
days
mtx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013510313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526545A5 (enExample
JP2013526545A (ja
Inventor
ルーイ ダニエル ガルシア，
ルーイ ダニエル ガルシア，
ルイス ギブソン，
ルイス ギブソン，
ウィリアム ランバート，
ウィリアム ランバート，
ベンジャミン リー，
ベンジャミン リー，
リャンジン ズー，
リャンジン ズー，
Original Assignee
パシラ ファーマシューティカルズ インコーポレーテッド
パシラ ファーマシューティカルズ インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パシラ ファーマシューティカルズ インコーポレーテッド, パシラ ファーマシューティカルズ インコーポレーテッド filed Critical パシラ ファーマシューティカルズ インコーポレーテッド
Publication of JP2013526545A publication Critical patent/JP2013526545A/ja
Publication of JP2013526545A5 publication Critical patent/JP2013526545A5/ja
Application granted granted Critical
Publication of JP5980775B2 publication Critical patent/JP5980775B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2013510313A 2010-05-13 2011-05-12 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤 Active JP5980775B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33454610P 2010-05-13 2010-05-13
US61/334,546 2010-05-13
US12/914,944 2010-10-28
US12/914,944 US9770414B2 (en) 2010-05-13 2010-10-28 Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
PCT/US2011/036328 WO2011143484A1 (en) 2010-05-13 2011-05-12 A sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015188829A Division JP6263508B2 (ja) 2010-05-13 2015-09-25 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤

Publications (3)

Publication Number Publication Date
JP2013526545A JP2013526545A (ja) 2013-06-24
JP2013526545A5 JP2013526545A5 (enExample) 2014-06-26
JP5980775B2 true JP5980775B2 (ja) 2016-08-31

Family

ID=44911988

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013510313A Active JP5980775B2 (ja) 2010-05-13 2011-05-12 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤
JP2015188829A Active JP6263508B2 (ja) 2010-05-13 2015-09-25 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤
JP2017013045A Withdrawn JP2017071652A (ja) 2010-05-13 2017-01-27 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015188829A Active JP6263508B2 (ja) 2010-05-13 2015-09-25 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤
JP2017013045A Withdrawn JP2017071652A (ja) 2010-05-13 2017-01-27 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤

Country Status (6)

Country Link
US (3) US9770414B2 (enExample)
EP (1) EP2568962B1 (enExample)
JP (3) JP5980775B2 (enExample)
CN (1) CN103002877B (enExample)
IL (1) IL222683B (enExample)
WO (1) WO2011143484A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871821C (en) 2012-05-10 2021-01-12 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
BR112015000174A2 (pt) 2012-07-05 2017-06-27 Taiwan Liposome Co Ltd método para o tratamento da artrite
WO2015147018A1 (ja) * 2014-03-28 2015-10-01 テルモ株式会社 炎症性自己免疫疾患治療用の注射用水性製剤
WO2015183213A1 (en) * 2014-05-28 2015-12-03 Onko İlaç Sanayi̇ Ve Ti̇caret A. Ş. Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid
JP7097181B2 (ja) 2014-07-30 2022-07-07 マサチューセッツ アイ アンド イヤー インファーマリー 増殖性硝子体網膜症用メトトレキサート
EP3231433B1 (en) * 2014-12-12 2023-12-27 Motejo. Ltd Agent for hypodermic injection
JP5774190B1 (ja) * 2014-12-12 2015-09-09 ジーンメディカル株式会社 皮下注射用剤及び皮下注射用剤を含有する注射器の製造方法
EP3317448B1 (en) 2015-06-30 2021-09-08 Tela Bio, Inc. Corner-lock stitch patterns
EP3324882B1 (en) 2015-07-21 2023-10-25 Tela Bio, Inc. Compliance control stitching in substrate materials
ES2943587T3 (es) 2015-11-24 2023-06-14 Massachusetts Inst Technology Sistemas para prevenir, atenuar y/o tratar demencia
US9820843B2 (en) 2016-04-26 2017-11-21 Tela Bio, Inc. Hernia repair grafts having anti-adhesion barriers
US20180236098A1 (en) 2016-08-12 2018-08-23 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
WO2018031980A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
AU2017308159B2 (en) * 2016-08-12 2023-08-10 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
KR102612531B1 (ko) 2016-11-17 2023-12-12 코그니토 쎄라퓨틱스, 인코포레이티드 인지 기능 개선을 위한 시스템
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
US10960225B2 (en) 2017-10-10 2021-03-30 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function
ES3058718T3 (en) 2017-10-10 2026-03-12 Massachusetts Inst Technology Systems for preventing, mitigating, and/or treating dementia
EP3710008A4 (en) 2017-11-14 2021-08-25 The Schepens Eye Research Institute, Inc. RUNX1 INHIBITION FOR THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY AND DISEASES ASSOCIATED WITH EPITHELIAL-MESENCHYMAL TRANSITION
CN115475142A (zh) * 2017-11-20 2022-12-16 平顶山学院 一种口服甲氨蝶呤脂质体及其制备方法
CN111954530A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 γ聚谷氨酸化培美曲塞及其用途
WO2019157125A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated methotrexate and uses thereof
JP7487107B2 (ja) * 2018-02-07 2024-05-20 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化葉酸代謝拮抗薬およびその使用
EP3749312A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF
WO2019157148A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
CA3090384A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
CA3090391A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
CA3090389A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
CN111954531A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化培美曲塞及其用途
EP3749319A4 (en) 2018-02-07 2022-06-22 L.E.A.F Holdings Group LLC TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
EP3749316A4 (en) 2018-02-07 2021-10-27 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED PRALATREXATE AND USES THEREOF
CA3090875A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
WO2019160736A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
US12048766B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
WO2019160733A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof
US11590262B2 (en) 2018-03-09 2023-02-28 Tela Bio, Inc. Surgical repair graft
US11446130B2 (en) 2019-03-08 2022-09-20 Tela Bio, Inc. Textured medical textiles
CN110269939A (zh) * 2019-03-12 2019-09-24 武汉愔紫生物科技有限公司 一种治疗真菌分泌蛋白介导的炎症疾病标志物的药物、药物组合物、用途及其使用方法
AU2021225926A1 (en) 2020-02-26 2022-10-20 Case Western Reserve University Compositions and methods for treating misfolded protein ocular disorders
WO2021216957A1 (en) * 2020-04-23 2021-10-28 Massachusetts Institute Of Technology Systems, devices, and methods for gamma entrainment using sensory stimuli to alleviate cognitive deficits and/or neuroinflammation induced by chemotherapy agents
CN114249731B (zh) * 2020-09-24 2023-09-29 南京海润医药有限公司 一种甲氨蝶呤中间体的精制方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4565696A (en) * 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
US5723147A (en) * 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes
US5807572A (en) * 1988-02-18 1998-09-15 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
NZ237464A (en) * 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
ATE227979T1 (de) 1993-04-22 2002-12-15 Skyepharma Inc Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
DK0729351T3 (da) 1993-11-16 2000-10-16 Skyepharma Inc Vesikler med reguleret afgivelse af aktivstoffer
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US5891467A (en) * 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6306432B1 (en) * 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
EP1028629A4 (en) * 1997-11-05 2003-06-04 Biozone Lab Inc IMPROVED FOOD PREPARATION FOR INFANTS CONTAINING NUTRIENTS AND ACTIVE SUBSTANCES ENCLOSED IN LIPOSOMES
ATE554748T1 (de) 1997-11-14 2012-05-15 Pacira Pharmaceuticals Inc Herstellung von multivesikulären liposomen
CN1635910A (zh) * 2001-05-02 2005-07-06 普渡研究基金会 巨噬细胞介导的疾病的治疗和诊断
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
US8043602B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US20040176381A1 (en) * 2003-03-06 2004-09-09 Walsh Michael J. Methotrexate compliance packaging
US6921667B2 (en) * 2003-03-07 2005-07-26 Prometheus Laboratories, Inc. Methods for direct detection of individual methotrexate metabolites
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
EP1791544A4 (en) 2004-09-08 2007-09-12 Chelsea Therapeutics Inc CHINAZOLINE DERIVATIVES AS METABOLIC INERT ANTIFOLATE
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
WO2006122414A1 (en) 2005-05-17 2006-11-23 Matregen Corp. Depot for sustained and controlled delivery of methotrexate
EP1904183B1 (en) * 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
DE602007007618D1 (de) * 2006-05-18 2010-08-19 Univ Muenchen L Maximilians Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
DE102006033837A1 (de) 2006-07-21 2008-01-31 Medac Gesellschaft für klinische Spezialpräparate m.b.H Konzentrierte Methotrexat-Lösungen
WO2008030818A2 (en) 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
US20080075807A1 (en) * 2006-09-22 2008-03-27 Baldwin Cheryl J Methods Of Fortifying Foods With Vitamin D And Food Products Thereof
GB2443738A (en) 2006-11-09 2008-05-14 Proprius Pharmaceuticals Inc A sustained release methotrexate composition and methods of use thereof
WO2009029543A1 (en) 2007-08-24 2009-03-05 Aegis Therapeutics, Llc Controlled release formulations
CN101965514A (zh) * 2008-01-03 2011-02-02 艾博特生物技术有限公司 预测化合物在治疗银屑病中的长期功效

Also Published As

Publication number Publication date
EP2568962B1 (en) 2017-11-29
JP2017071652A (ja) 2017-04-13
IL222683A0 (en) 2012-12-31
JP2015232049A (ja) 2015-12-24
CN103002877B (zh) 2017-07-21
JP6263508B2 (ja) 2018-01-17
EP2568962A1 (en) 2013-03-20
WO2011143484A1 (en) 2011-11-17
US20130183370A1 (en) 2013-07-18
US20130183371A1 (en) 2013-07-18
US10028911B2 (en) 2018-07-24
EP2568962A4 (en) 2014-06-18
US9770414B2 (en) 2017-09-26
US20110280932A1 (en) 2011-11-17
JP2013526545A (ja) 2013-06-24
IL222683B (en) 2018-04-30
CN103002877A (zh) 2013-03-27

Similar Documents

Publication Publication Date Title
JP6263508B2 (ja) 疾患修飾性抗リウマチ薬（ｄｍａｒｄ）および抗癌剤としてのメトトレキサートの持続性放出製剤
AU2019261329B2 (en) Inhalable liposomal sustained release composition for use in treating pulmonary diseases
JP5645954B2 (ja) イリノテカン又はその塩酸塩のリポソーム及びその製造方法
JP5813011B2 (ja) リポソーム組成物およびその製造方法
US12539274B2 (en) Zinc meloxicam complex microparticle multivesicular liposome formulations and processes for making the same
CN103370055B (zh) 缓释性脂质体组合物及其制造方法
Layek et al. Recent advances in lipid-based nanodrug delivery systems in cancer therapy
JP6705933B2 (ja) リポソーム組成物およびその製造方法
JP2024095802A (ja) カルベジロール分散系の非経口徐放送達
AU2006307460A1 (en) A method for preparing liposomes and uses thereof
CN107708670A (zh) 磷脂包衣的治疗剂纳米颗粒和有关的方法
JP5705978B2 (ja) 溶解度が向上した難溶性トリサイクリック誘導体の薬学的組成物
HK1183229B (en) A sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent
HK1183229A (en) A sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent
CN112773776A (zh) 一种载药纳米粒体系
TWI500430B (zh) 伊立替康或鹽酸伊立替康脂質體及其製備方法
WO2025125241A1 (en) Pharmaceutical composition
HK40043569A (en) Inhalable liposomal sustained release composition for use in treating pulmonary diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140509

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150925

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160425

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160610

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160727

R150 Certificate of patent or registration of utility model

Ref document number: 5980775

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250